Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors



Status:Active, not recruiting
Conditions:Skin Cancer, Cancer, Cancer, Brain Cancer, Brain Cancer, Endocrine
Therapuetic Areas:Endocrinology, Oncology
Healthy:No
Age Range:2 - 18
Updated:3/14/2019
Start Date:November 14, 2012

Use our guide to learn which trials are right for you!

A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors

This phase I trial studies the side effects and best dose of cabozantinib S-malate in
treating younger patients with solid tumors that have come back or no longer respond to
treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of XL184
(cabozantinib) (cabozantinib S-malate) administered orally to children with refractory solid
tumors including central nervous system (CNS) tumors.

II. To define and describe the toxicities of XL184 (cabozantinib) administered on this
schedule.

III. To characterize the pharmacokinetics of XL184 (cabozantinib) in children with refractory
solid tumors.

SECONDARY OBJECTIVES:

I. To preliminarily define the antitumor activity of XL184 (cabozantinib) within the confines
of a phase 1 study.

II. To assess the biologic activity of XL184 (cabozantinib). III. To assess the biomarker
response (carcinoembryonic antigen [CEA] and calcitonin) in patients with medullary thyroid
cancer treated with XL184.

IV. To evaluate overall survival from study entry through a five-year follow-up period.

OUTLINE: This is a dose-escalation study. (Complete as of 4/16/2014)

Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-28. Courses
repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, 6 months, and then
annually for up to 60 months.

Inclusion Criteria:

- Patients must have a body surface area >= 0.44 m^2 when enrolling on dose level -1;
patients must have a body surface area >= 0.35 m^2 when enrolling on dose level 1, 2,
or 3

- PART A: Patients with relapsed or refractory solid tumors (excluding medullary thyroid
cancer) including CNS tumors and malignant melanoma are eligible; patients must have
had histologic verification of malignancy at original diagnosis or relapse except in
patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with
pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers
including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)

- Part B: Patients with medullary thyroid cancer (MTC), with or without bone marrow
involvement, will be eligible for Part B; these patients will be enrolled at dose
level 2, the recommended phase 2 dose determined in the dose escalation part of the
study

- Patients must have either measurable or evaluable disease

- Patient's current disease state must be one for which there is no known curative
therapy or therapy proven to prolong survival with an acceptable quality of life

- Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16
years of age

- Note: neurologic deficits in patients with CNS tumors must have been relatively
stable for at least 7 days prior to study enrollment; patients who are unable to
walk because of paralysis, but who are up in a wheelchair, will be considered
ambulatory for the purpose of assessing the performance score

- Patients must have fully recovered from the acute toxic effects of all prior
anti-cancer chemotherapy:

- Myelosuppressive chemotherapy: at least 21 days after the last dose of
myelosuppressive chemotherapy (42 days if prior nitrosourea)

- Hematopoietic growth factors: at least 14 days after the last dose of a
long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth
factor; for agents that have known adverse events occurring beyond 7 days after
administration, this period must be extended beyond the time during which adverse
events are known to occur; the duration of this interval must be discussed with
the study chair

- Biologic (anti-neoplastic agent): at least 7 days after the last dose of a
biologic agent; for agents that have known adverse events occurring beyond 7 days
after administration, this period must be extended beyond the time during which
adverse events are known to occur; the duration of this interval must be
discussed with the study chair

- Immunotherapy: at least 42 days after the completion of any type of
immunotherapy, e.g. tumor vaccines

- Monoclonal antibodies: at least 3 half-lives of the antibody after the last dose
of a monoclonal antibody

- Radiation therapy (XRT): at least 14 days after local palliative XRT (small
port); at least 150 days must have elapsed if prior total-body irradiation (TBI),
craniospinal XRT or if >= 50% radiation of pelvis; at least 42 days must have
elapsed if other substantial bone marrow (BM) radiation

- Stem cell infusion without TBI: no evidence of active graft versus (vs.) host
disease and at least 56 days must have elapsed after transplant or stem cell
infusion

- For patients with solid tumors without known bone marrow involvement:

- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3

- Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving
platelet transfusions for at least 7 days prior to enrollment)

- Patients with known bone marrow metastatic disease will be eligible for study provided
they meet the blood counts (may receive transfusions provided they are not known to be
refractory to red cell or platelet transfusions); these patients will not be evaluable
for hematologic toxicity; at least 5 of every cohort of 6 patients with a solid tumor
must be evaluable for hematologic toxicity in the dose-escalation part of the study;
if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled
must be evaluable for hematologic toxicity

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

- 2 to < 6 years: 0.8 mg/dL

- 6 to < 10 years: 1 mg/dL

- 10 to < 13 years: 1.2 mg/dL

- 13 to < 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female)

- >= 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female)

- Urine protein: =< 30 mg/dl in urinalysis or =< 1+ on dipstick, unless quantitative
protein is < 1000 mg in a 24 hour (h) urine sample

- Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for
age

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110
U/L; for the purpose of this study, the ULN for SGPT is 45 U/L

- Serum albumin >= 2.8 g/dL

- Prothrombin time (PT) and international normalized ratio (INR) =< 1.5 x ULN

- Serum amylase =< 1.5 x ULN

- Serum lipase =< 1.5 x ULN

- A blood pressure (BP) =< the 95th percentile for age, height, and gender, and not
receiving medication for treatment of hypertension; please note that 3 serial blood
pressures should be obtained and averaged to determine baseline BP

- Central nervous system function defined as: patients with seizure disorder may be
enrolled if receiving non-enzyme inducing anticonvulsants and well controlled

- No history of congenital prolonged corrected QT interval (QTc) syndrome, New York
Heart Association (NYHA) class III or IV congestive heart failure (CHF)

- No clinically significant cardiac arrhythmias, stroke or myocardial infarction within
6 months prior to enrollment

- QTc =< 480 msec; Note: patients with grade 1 prolonged QTc (450-480 msec) at the time
of study enrollment should have correctable causes of prolonged QTc addressed if
possible (i.e. electrolytes, medications)

- All patients and/or their parents or legally authorized representatives must sign a
written informed consent; assent, when appropriate, will be obtained according to
institutional guidelines

- Archival tumor tissue slides from either initial diagnosis or relapse must be sent; if
tumor tissue is unavailable, the study chair must be notified prior to enrollment

Exclusion Criteria:

- Pregnant or breast-feeding women will not be entered on this study; pregnancy tests
must be obtained in girls who are post-menarchal; males or females of reproductive
potential may not participate unless they have agreed to use two methods of birth
control - a medically accepted barrier method of contraceptive method (e.g., male or
female condom) and a second effective contraceptive method of birth control - during
protocol therapy and for at least 4 months after the last dose of XL184; abstinence is
an acceptable method of birth control

- Patients receiving corticosteroids who have not been on a stable or decreasing dose of
corticosteroid for at least 7 days prior to enrollment are not eligible

- Patients who are currently receiving another investigational drug are not eligible

- Patients who are currently receiving other anti-cancer agents are not eligible

- Patients who are receiving cyclosporine, tacrolimus or other agents to prevent
graft-versus-host disease post bone marrow transplant are not eligible for this trial

- Patients must not be receiving any of the following potent cytochrome P450 family 3,
subfamily A, polypeptide 4 cytochrome (CYP3A4) inducers or inhibitors: erythromycin,
clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St.
John's wort

- Patients who are receiving systemic treatment anticoagulation are not eligible;
patients receiving prophylactic systemic anticoagulation will be allowed as long as
eligibility PT/INR requirements are met

- Patients must not have received enzyme-inducing anticonvulsants within 14 days prior
to enrollment

- Patients who are receiving drugs that prolong QTc are not eligible

- Patients must be able to swallow intact tablets; patients who cannot swallow intact
tablets are not eligible

- Patients with active bleeding are not eligible; specifically, no clinically
significant gastrointestinal (GI) bleeding, GI perforation, intra-abdominal abscess or
fistula for 6 months prior to enrollment, no hemoptysis or other signs of pulmonary
hemorrhage for 3 months prior to enrollment

- Patients with evidence of an acute intracranial or intratumoral hemorrhage on computed
tomography (CT) or magnetic resonance imaging (MRI) are not eligible (patients with
evidence of resolving hemorrhage will be eligible)

- Patients who have had or are planning to have the following invasive procedures are
not eligible:

- Major surgical procedure, laparoscopic procedure, open biopsy or significant
traumatic injury within 28 days prior to enrollment

- Central line placement or subcutaneous port placement is not considered major
surgery but must be placed at least 3 days prior to enrollment for external lines
(e.g. Hickman or Broviac) and at least 7 days prior to enrollment for
subcutaneous port

- Core biopsy within 7 days prior to enrollment

- Fine needle aspirate within 7 days prior to enrollment

- Surgical or other wounds must be adequately healed prior to enrollment

- Patients on antihypertensive therapy for control of blood pressure at the time of
enrollment are not eligible

- Patients with any medical or surgical conditions that would interfere with
gastrointestinal absorption of this oral agent are not eligible

- Patients who have an uncontrolled infection are not eligible

- Patients who have received a prior solid organ transplantation are not eligible

- Patients who in the opinion of the investigator may not be able to comply with the
safety monitoring requirements of the study are not eligible
We found this trial at
23
sites
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
(205) 638-9100
Children's Hospital of Alabama Children
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
(877) 475-6688
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
9000 Rockville Pike
Bethesda, Maryland 20892
301-496-2563
National Institutes of Health Clinical Center The National Institutes of Health (NIH) Clinical Center in...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Chicago, Illinois 60614
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
705 Riley Hospital Dr
Indianapolis, Indiana 46202
(317) 944-5000
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
9000 W Wisconsin Ave #270
Milwaukee, Wisconsin 53226
(414) 266-2000
Children's Hospital of Wisconsin Nothing matters more than our children. At Children's Hospital of Wisconsin,...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
San Francisco, California 94158
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
555 University Avenue
Toronto, Ontario M5G 1X8
?
mi
from
Toronto,
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials